Draft Guidance Says Asymptomatic People Should Be Included in Alzheimer’s Trials
Drugs for cognitively and functionally normal people who have the pathophysiologic changes of Alzheimer’s disease (AD) could be approved on a single biomarker outcome, according to the FDA’s new draft…